(VIANEWS) – Lantheus Holdings (LNTH), TriMas Corporation (TRS), DexCom (DXCM) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Lantheus Holdings (LNTH)
23.4% sales growth and 5.96% return on equity
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.
Earnings Per Share
As for profitability, Lantheus Holdings has a trailing twelve months EPS of $0.54.
PE Ratio
Lantheus Holdings has a trailing twelve months price to earnings ratio of 126.65. Meaning, the purchaser of the share is investing $126.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.96%.
Moving Average
Lantheus Holdings’s worth is under its 50-day moving average of $69.23 and below its 200-day moving average of $74.48.
Sales Growth
Lantheus Holdings’s sales growth is 37.8% for the current quarter and 23.4% for the next.
Volume
Today’s last reported volume for Lantheus Holdings is 1285480 which is 23.46% above its average volume of 1041180.
Yearly Top and Bottom Value
Lantheus Holdings’s stock is valued at $68.39 at 20:22 EST, way below its 52-week high of $100.85 and way higher than its 52-week low of $47.46.
Previous days news about Lantheus Holdings(LNTH)
- Lantheus holdings (lnth) falls more steeply than broader market: what investors need to know. According to Zacks on Thursday, 19 October, "In the latest market close, Lantheus Holdings (LNTH Quick QuoteLNTH – Free Report) reached $69.21, with a -1.8% movement compared to the previous day. ", "With respect to valuation, Lantheus Holdings is currently being traded at a Forward P/E ratio of 12.4. "
2. TriMas Corporation (TRS)
23.2% sales growth and 7.43% return on equity
TriMas Corporation manufactures and provides products for consumer products, aerospace, and industrial end markets worldwide. It operates in three segments: Packaging, Aerospace, and Specialty Products. The Packaging segment offers specialty polymeric and steel closure and dispensing systems, including dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, flexible spouts, and agricultural closures; polymeric jar products; integrated dispensers; bag-in-box products; aseptic closures; industrial closures and flex spouts; and single-bodied and assembled caps and closures under the Rieke, Taplast, Affaba & Ferrari, Stolz, and Rapak brands. The Aerospace segment provides fasteners, collars, blind bolts, rivets, ducting and connectors for air management systems, and machined parts and components to original equipment manufacturers, supply chain distributors, MRO/aftermarket providers, and tier one suppliers for commercial, maintenance, repair, and operations (MRO); and military and defense aerospace applications and platforms under the Monogram Aerospace Fasteners, Allfast Fastening Systems, Mac Fasteners, RSA Engineered Products, and Martinic Engineering brands. The Specialty Products segment offers steel cylinders for use in the transportation, storage, and dispensing of compressed gases under the Norris Cylinder brand; natural gas powered wellhead engines, compressors, and replacement parts for oil and natural gas production, and other industrial and commercial markets under the Arrow brand; and spare parts for various industrial engines. The company sells its products through a direct sales force, third-party agents, and distributors. TriMas Corporation was incorporated in 1986 and is headquartered in Bloomfield Hills, Michigan.
Earnings Per Share
As for profitability, TriMas Corporation has a trailing twelve months EPS of $1.14.
PE Ratio
TriMas Corporation has a trailing twelve months price to earnings ratio of 21.25. Meaning, the purchaser of the share is investing $21.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.43%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 37.5% and a drop 11.3% for the next.
Sales Growth
TriMas Corporation’s sales growth is 0.2% for the ongoing quarter and 23.2% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.9%, now sitting on 870.49M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
TriMas Corporation’s EBITDA is 41.87.
3. DexCom (DXCM)
22% sales growth and 16.41% return on equity
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $0.86.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 101.06. Meaning, the purchaser of the share is investing $101.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.41%.
Yearly Top and Bottom Value
DexCom’s stock is valued at $86.91 at 20:22 EST, way under its 52-week high of $139.55 and way above its 52-week low of $74.75.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 21.4% and 11.8%, respectively.
Moving Average
DexCom’s worth is way below its 50-day moving average of $99.04 and way below its 200-day moving average of $113.58.
Sales Growth
DexCom’s sales growth is 25% for the current quarter and 22% for the next.
4. RCI Hospitality Holdings (RICK)
10.4% sales growth and 14.64% return on equity
RCI Hospitality Holdings, Inc., through its subsidiaries, engages in the hospitality and related businesses in the United States. The company operates through Nightclubs, Bombshells, and Other segments. It owns and/or operates upscale adult nightclubs serving primarily businessmen and professionals under the Rick's Cabaret, Jaguars Club, Tootsie's Cabaret, XTC Cabaret, Club Onyx, Hoops Cabaret and Sports Bar, Scarlett's Cabaret, Temptations Adult Cabaret, Foxy's Cabaret, Vivid Cabaret, Downtown Cabaret, Cabaret East, The Seville, Silver City Cabaret, and Kappa Men's Club. The company also operates restaurants and sports bars under the Bombshells Restaurant & Bar brand, as well as a dance club under the Studio 80 brand. In addition, it owns two national industry trade publications serving the adult nightclubs industry and the adult retail products industry; a national industry convention and tradeshow; and two national industry award shows, as well as approximately a dozen industry and social media Websites. Further, RCI Hospitality Holdings, Inc. holds license to sell Robust Energy Drink in the United States. The company was formerly known as Rick's Cabaret International, Inc. and changed its name to RCI Hospitality Holdings, Inc. in August 2014. RCI Hospitality Holdings, Inc. was founded in 1983 and is based in Houston, Texas.
Earnings Per Share
As for profitability, RCI Hospitality Holdings has a trailing twelve months EPS of $4.06.
PE Ratio
RCI Hospitality Holdings has a trailing twelve months price to earnings ratio of 13.34. Meaning, the purchaser of the share is investing $13.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.64%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Sep 13, 2023, the estimated forward annual dividend rate is 0.24 and the estimated forward annual dividend yield is 0.45%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 10.3% and a negative 4.2%, respectively.
Moving Average
RCI Hospitality Holdings’s worth is way under its 50-day moving average of $62.38 and way below its 200-day moving average of $75.13.
Sales Growth
RCI Hospitality Holdings’s sales growth is 6.4% for the ongoing quarter and 10.4% for the next.
